HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31

Helus Pharma Inc.

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 40-F on Jun 29, 2026

$10.69+0.14 (+1.33%)

Close on Oct 19, 2026

Helus Pharma Inc. cash flow statement

AnnualQuarterlyTTM

CAD USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Depreciation & Amortization	0.34	0.31	0.19	–	–
Stock-Based Compensation	31	10	3.54	14	8.73
Change in Accounts Receivable	-1.01	-0.81	-0.72	-0.62	-1.12
Change in Inventory	–	–	–	0	-0.39
Operating Cash Flow	-73	-51	-36	-36	-14
Capital Expenditures	–	-0.02	-0.11	-0.08	-0.10
Investing Cash Flow	-1.41	5.13	-2.50	-0.61	-0.90
Stock Issued	15	189	9.98	25	58
Financing Cash Flow	15	189	10	29	63
Foreign Exchange Rate Adjustments	6.54	-0.12	0.13	-0.15	-0.02
Net Change in Cash	-53	143	-28	-8.28	47
Free Cash Flow	–	-51	-36	-36	-14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.